ga naar hoofdinhoud
Informatie voor zorgverleners Behandelprotocollen Chronische myelomonocytaire leukemie (CMML) Richtlijnen en literatuur

Richtlijnen

Klik HIER voor de richtlijn 'Chronische myelomonocytaire leukemie' van de EHA en ELN (afgeschermd met inlog). 

Literatuur  

  1. Itzykson R. et al. Diagnosis and treatment of chronic myelomonocytic leukemias in adults: recommendations from the European Hematology Association and the European LeukemiaNet. HemaSphere 2018;2:6
  2. Khoury et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia 2022, vol. 36, issue 7, pages 1703-1719
  3. Arber DA et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140(11):1200-28
  4. Solary E. et al. How I treat CMML. Blood 2017,130;126-136
  5. Wagner-Ballon et al. ELN iMDS flow working group validation of the monocyte assay for chronic myelomonocytic leukemia diagnosis by flow cytometry. Cytometry B Clin Cytom 104(1): 66-76
  6. Malcovati L et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood 2013 122:2943-2964
  7. Itzykson R. et al. Prognostic score including gene mutations in chronic myelomonocytic leukemia. J Clin Oncol. 2013 Jul 1;31(19):2428-36
  8. Elena C. et al. Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia. Blood. 2016 Sep 8;128(10):1408-17
  9. Savona M.R. et al. An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults, Blood 2015 125: 1857-1865
  10. Symeonidis A. et al. Achievement of complete remission predicts outcome of allogeneic haematopoietic stem cell transplantation in patients with chronic myelomonocytic leukaemia. A study of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation. Br. J. Haematol. 2015 Oct;171(2):239-246
  11. Such E et al. Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia. Blood 2013;121(15):3005-15
  12. Gagelmann N et al. A prognostic score including mutation profile and clinical features for patients with CMML undergoing stem cell transplantation. Blood Adv 2021;5(6):1760-9
  13. Palomo L et al. Molecular landscape and clonal architecture of adult myelodysplastic/ myeloproliferative neoplasms. Blood 2020;136(16):1851-62
  14. Mughal TI et al. An International MDS/MPN working group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/ myeloproliferative neoplasms. Haematologica 2015;100(9):1117-30
  15. Pleyer L. et al. Outcomes of patients with chronic myelomonocytic leukaemia treated with non-curative therapies: a retrospective cohort study. Lancet Haematol. 2021;8(2):e135-e48
  16. Itzykson et al. Decitabine versus hydroxyurea for advanced proliferatieve chronic myelomonocytic leukemia: results of a randomized phase III trial within the EMSCO network. J Clin Oncol. 2023 Apr 1; 410(10):1888-1897
  17. van Zeventer IA et al. Monocytosis and its association with clonal hematopoiesis in community-dwelling individuals. Blood Adv. 2022; 6(14):4174-84
  18. Cargo C et al. The use of targeted sequencing and flow cytometry to identify patients with a clinically significant monocytosis. Blood. 2019; 133(12):1325-34

 

Ga terug naar de CMML homepage of lees meer over CMML:

Ga terug naar de algemene homepage Behandelprotocollen.